Sun Pharma's relationship with AML is on an arm's-length basis. As investors have expressed concerns regarding this arrangement, we are in the process of evaluating various options for undertaking domestic formulation business. — Dilip Shanghvi Copy Share Image
Generally, we have competed with ourselves... because I feel that if I compete against somebody, it causes stress. I don't want the process of… — Dilip Shanghvi Copy Share Image
Our focus is to see that we are growing faster than the industry and, whichever product we launch, we do better than competition. We… — Dilip Shanghvi Copy Share Image
Sun is seeking some products that we don't have or technologies that we don't have. — Dilip Shanghvi Copy Share Image
The Ranbaxy acquisition doesn't preclude us from making more large acquisitions. The important issue is whether we have the management bandwidth to handle the… — Dilip Shanghvi Copy Share Image
Sun Pharma's relationship with AML is on an arm's-length basis. As investors have expressed concerns regarding this arrangement, we are in the process of… — Dilip Shanghvi Copy Share Image
The reason we don't give a date by which we will acquire something is because we don't want to create pressure on ourselves to… — Dilip Shanghvi Copy Share Image
India is a large market where our focus will be to grow faster than the market and add few percentage points to our market… — Dilip Shanghvi Copy Share Image
We follow highest level of corporate governance, which is in line with a global company like ours. — Dilip Shanghvi Copy Share Image
